위더스제약
Financials
Valuation Metrics
위더스제약's Market Cap is ₩970B. At end of 2025 it was ₩1138B. Ranked #1300 of 2,421 in KR market (top 54%), #715 of 1,640 on KOSDAQ (top 44%), #144 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 97.02B KRW | KR#1,300/2,421 Sec#144/231 |
| Revenue | 111.72B KRW | KR#1,355/2,421 Sec#86/231 |
| Net Income | 7.96B KRW | KR#1,041/2,421 Sec#65/231 |
| Total Assets | 144.03B KRW | KR#1,537/2,421 Sec#115/231 |
| Net Assets | 103.94B KRW | KR#1,387/2,421 Sec#109/231 |
| Employees | 218 | KR#1,033/2,421 Sec#85/231 |
| Value | ||
| P/E | 12.18x | KR#933/2,421 Sec#52/231 |
| P/B | 0.93x | KR#1,399/2,421 Sec#87/231 |
| PEG | 0.37x | KR#655/2,421 Sec#39/231 |
| P/S | 0.87x | KR#1,291/2,421 Sec#75/231 |
| EV/EBITDA | 23.64x | KR#1,089/2,421 Sec#66/231 |
| FCF Yield | 5.65% | KR#812/2,421 Sec#41/231 |
| Profitability | ||
| ROE | 7.66% | KR#823/2,421 Sec#57/231 |
| ROA | 5.53% | KR#677/2,421 Sec#55/231 |
| Op. Margin | 3.65% | KR#1,144/2,421 Sec#83/231 |
| Revenue Growth | 9.00% | KR#958/2,421 Sec#93/231 |
| Earnings Growth | 33.19% | KR#629/2,421 Sec#42/231 |
| Financial Health | ||
| Debt Ratio | 38.58% | KR#758/2,421 Sec#90/231 |
| Total Debt | 18.17B KRW | KR#1,410/2,421 Sec#114/231 |
| FCF | 5.48B KRW | KR#881/2,421 Sec#59/231 |
| Cash | 18.87B KRW | KR#1,280/2,421 Sec#95/231 |
| Current Ratio | 2.04x | KR#850/2,421 Sec#96/231 |
| Net Debt/EBITDA | -0.17x | KR#574/2,421 Sec#33/231 |
| Dividend | ||
| Div. Growth | 108.40% | KR#110/2,421 Sec#3/231 |
| Performance | ||
| 1Y Return | 1.24% | KR#709/2,421 Sec#45/231 |
| 1M Return | -6.84% | KR#1,920/2,421 Sec#157/231 |
| From 52W High | -38.49% | KR#857/2,421 Sec#60/231 |
| 1Y MDD | -49.66% | KR#973/2,421 Sec#79/231 |
| Trading | ||
| Volume | 59,925 shares | KR#1,034/2,421 Sec#103/231 |
| Trading Value | 442.7M KRW | KR#968/2,421 Sec#97/231 |
| Foreign Own. | 1.33% | KR#1,899/2,421 Sec#186/231 |
| Per Share | ||
| EPS | 603 KRW | KR#923/2,421 Sec#63/231 |
| BPS | 7,874 KRW | KR#1,133/2,421 Sec#81/231 |
Company Info
Withus Pharmaceutical, headquartered in Seocho-gu, Seoul, was established in 2004 and listed on KOSDAQ in 2020, with its primary business being the production and sale of specialized medicines. The company demonstrates strengths in cardiovascular drugs, operates cephalosporin antibiotic production facilities, and engages in Contract Manufacturing Organization (CMO) services. To expand its market share in aging population and chronic disease markets, Withus Pharmaceutical is strengthening its product lineup and pharmaceutical pipeline. It is also enhancing capabilities by securing manufacturing technologies through strategic collaborations.